Aurinia faces choppy waters amid lower-than-expected 2022 guidance and patent challenge on Lupkynis
A new patent challenge to Aurinia Pharmaceuticals’ lupus nephritis drug Lupkynis is adding to the biopharma’s woes this week. Sun Pharmaceutical is challenging Aurinia’s “treatment protocol” patent, the company revealed in a 10-K filing this week first reported by STAT.
Aurinia pushed back on the news report, pointing out, in a statement to Endpoints News, that the patent has already been through “significant review” with the US Patent and Trademark Office before Lupkynis was approved by the FDA in January 2021.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.